Reda G. Yousef

1.0k total citations
41 papers, 875 citations indexed

About

Reda G. Yousef is a scholar working on Molecular Biology, Toxicology and Organic Chemistry. According to data from OpenAlex, Reda G. Yousef has authored 41 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 20 papers in Toxicology and 17 papers in Organic Chemistry. Recurrent topics in Reda G. Yousef's work include Bioactive Compounds and Antitumor Agents (20 papers), Synthesis and biological activity (15 papers) and Angiogenesis and VEGF in Cancer (15 papers). Reda G. Yousef is often cited by papers focused on Bioactive Compounds and Antitumor Agents (20 papers), Synthesis and biological activity (15 papers) and Angiogenesis and VEGF in Cancer (15 papers). Reda G. Yousef collaborates with scholars based in Egypt, Saudi Arabia and United States. Reda G. Yousef's co-authors include Ibrahim H. Eissa, Ahmed M. Metwaly, Eslam B. Elkaeed, Hazem Elkady, Dalal Z. Husein, Ibrahim M. Ibrahim, Ahmed B. M. Mehany, Aisha A. Alsfouk, Bshra A. Alsfouk and Mostafa A. Elhendawy and has published in prestigious journals such as PLoS ONE, Molecules and RSC Advances.

In The Last Decade

Reda G. Yousef

40 papers receiving 871 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Reda G. Yousef Egypt	17	533	496	198	167	158	41	875
Alaa Elwan Egypt	18	629 1.2×	545 1.1×	212 1.1×	111 0.7×	181 1.1×	37	992
Abdel‐Ghany A. El‐Helby Egypt	19	869 1.6×	576 1.2×	164 0.8×	86 0.5×	180 1.1×	20	1.2k
Helmy Sakr Egypt	21	1.0k 1.9×	689 1.4×	187 0.9×	101 0.6×	222 1.4×	39	1.4k
Mohammed S. Taghour Egypt	21	911 1.7×	701 1.4×	246 1.2×	158 0.9×	231 1.5×	33	1.3k
Mostafa A. Elhendawy Egypt	13	626 1.2×	444 0.9×	162 0.8×	117 0.7×	123 0.8×	20	950
Han‐Yue Qiu China	19	625 1.2×	379 0.8×	200 1.0×	86 0.5×	125 0.8×	52	967
Rezk R. Ayyad Egypt	25	1.1k 2.1×	691 1.4×	119 0.6×	98 0.6×	174 1.1×	52	1.5k
Hazem A. Mahdy Egypt	21	1.2k 2.2×	870 1.8×	291 1.5×	158 0.9×	270 1.7×	48	1.7k
Mohamed Ayman El‐Zahabi Egypt	15	519 1.0×	420 0.8×	115 0.6×	45 0.3×	127 0.8×	43	751
Hadia Almahli United Kingdom	17	529 1.0×	371 0.7×	55 0.3×	58 0.3×	99 0.6×	30	749

Countries citing papers authored by Reda G. Yousef

Since Specialization

Citations

This map shows the geographic impact of Reda G. Yousef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reda G. Yousef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reda G. Yousef more than expected).

Fields of papers citing papers by Reda G. Yousef

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reda G. Yousef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reda G. Yousef. The network helps show where Reda G. Yousef may publish in the future.

Co-authorship network of co-authors of Reda G. Yousef

This figure shows the co-authorship network connecting the top 25 collaborators of Reda G. Yousef. A scholar is included among the top collaborators of Reda G. Yousef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reda G. Yousef. Reda G. Yousef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elgammal, Walid E., Hazem Elkady, Reda G. Yousef, et al.. (2025). New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation. RSC Advances. 15(18). 14477–14498. 4 indexed citations

Elkaeed, Eslam B., Hazem Elkady, Reda G. Yousef, et al.. (2025). Development of novel furan-based VEGFR-2 inhibitors and apoptotic inducers for colorectal cancer. Future Medicinal Chemistry. 17(24). 2959–2973.

Yousef, Reda G., Souad A. El‐Metwally, Aisha A. Alsfouk, et al.. (2025). Discovery of new thieno[2,3-d]pyrimidine-based dual VEGFR-2 and EGFR inhibitors for enhanced therapeutic efficacy in breast cancer. Journal of Molecular Structure. 1341. 142586–142586. 1 indexed citations

Elkaeed, Eslam B., Hazem Elkady, Reda G. Yousef, et al.. (2025). Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer. PLoS ONE. 20(1). e0316146–e0316146. 1 indexed citations

Eissa, Ibrahim H., Reda G. Yousef, Hazem Elkady, et al.. (2024). Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor. Journal of Chemistry. 2024. 1–25. 2 indexed citations

Saleh, Tareq, et al.. (2024). Beta Catenin Expression in Colorectal Carcinoma and its relation to survival and prognostic factors. Annals of Cancer Research and Therapy. 32(1). 10–16. 3 indexed citations

Yousef, Reda G., Ibrahim H. Eissa, Hazem Elkady, et al.. (2024). Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers. Future Medicinal Chemistry. 16(24). 2583–2598. 4 indexed citations

Yousef, Reda G., et al.. (2024). Brain-derived neurotrophic factor (BDNF) Single nucleotide gene polymorphism and Nerve growth factor are risk factors that increase the severity of Allergic Rhinitis. Egyptian Journal of Chemistry. 0(0). 0–0. 1 indexed citations

Yousef, Reda G., Alaa Elwan, Abdallah E. Abdallah, et al.. (2024). Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors. Journal of Molecular Structure. 1305. 137753–137753. 11 indexed citations

10.

Yousef, Reda G., Ibrahim H. Eissa, Hazem Elkady, et al.. (2023). New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis, in vitro , and in silico studies. Journal of Biomolecular Structure and Dynamics. 43(4). 2120–2137. 10 indexed citations

11.

Eissa, Ibrahim H., Reda G. Yousef, Hazem Elkady, et al.. (2023). A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies. ChemistryOpen. 12(10). e202300066–e202300066. 11 indexed citations

12.

Eissa, Ibrahim H., Reda G. Yousef, Hazem Elkady, et al.. (2023). New theobromine derivative as apoptotic anti-triple-negative breast cancer targeting EGFR protein: CADD story. Journal of Molecular Structure. 1294. 136336–136336. 36 indexed citations

13.

Eissa, Ibrahim H., Eslam B. Elkaeed, Eslam B. Elkaeed, et al.. (2023). Design, Molecular Modeling, MD Simulations, Essential Dynamics, ADMET, DFT,Synthesis, Anti-proliferative, and Apoptotic Evaluations of a New Anti-VEGFR-2Nicotinamide Analogue. Current Pharmaceutical Design. 29(36). 2902–2920. 2 indexed citations

14.

Eissa, Ibrahim H., Reda G. Yousef, Hazem Elkady, et al.. (2023). Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2. Saudi Pharmaceutical Journal. 31(12). 101852–101852. 12 indexed citations

15.

Eissa, Ibrahim H., Reda G. Yousef, Hazem Elkady, et al.. (2023). Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers. Computational Biology and Chemistry. 107. 107953–107953. 34 indexed citations

16.

Elkaeed, Eslam B., Reda G. Yousef, Mohamed M. Khalifa, et al.. (2022). Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies. Molecules. 27(19). 6203–6203. 33 indexed citations

17.

Yousef, Reda G., Mohamed M. Khalifa, Wagdy M. Eldehna, et al.. (2022). Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 1389–1403. 45 indexed citations

18.

Yousef, Reda G., Wagdy M. Eldehna, Alaa Elwan, et al.. (2022). Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2. Molecules. 27(13). 4079–4079. 17 indexed citations

19.

Ran, Feng, Wendong Li, Yi Qin, et al.. (2021). Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation. Oxidative Medicine and Cellular Longevity. 2021(1). 8321400–8321400. 31 indexed citations

20.

El‐Adl, Khaled, Helmy Sakr, Reda G. Yousef, et al.. (2021). Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorganic Chemistry. 114. 105105–105105. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact